Flex Pharma, which is developing dietary supplements for the treatment of muscle cramps and spasms, filed on Monday with the SEC to raise up to $60 million in an initial public offering. The Boston, MA-based company, which was founded in 2014, plans to list on the NASDAQ under the symbol FLKS. Flex Pharma initially filed confidentially on October 29, 2014. Jefferies and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
